EGFR and non-small cell lung carcinoma: FLAURA was a randomized, double-blind phase 3 trial designed to explore the efficacy and safety of osimertinib versus first-generation EGFR-TKI (gefitinib or erlotinib) in the first-line therapy for patients with EGFR mutation-positive advanced NSCLC.